Catriona Yale, Chief Development Officer at Akero Therapeutics, Inc. (AKRO), sold 949 shares at $27.61 ($26K) on 2024-09-03, disclosed to the SEC on 2024-09-05.
Scheduled sale ($26k) by Chief Development Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| Filing → |
| AKRO | SELL | 2025-06-20 | $876K | — | Filing → |
| AKRO | SELL | 2025-06-20 | $179K | — | Filing → |
| AKRO | SELL | 2025-06-12 | $151K | — | Filing → |